GIST News A Wave of Information By the LIFE RAFT GROUP

Make a difference - Donate Today

  • Print
  • Email

Archive

April 2007

April 2007 clinical trial update

Written by Jim Hughes

 

BMS-354825

The BMS- 354825 trial has closed and is removed from the list. Dr. Demetri indicated that trial patients still continue to receive the drug. He also expects the results of the phase I trial to be published. BMS- 354825 has been approved for use in CML (as Sprycel) and will likely be tested in other cancers.

Genasense

According to Dr. Demetri’s staff, the Genasense phase I trial is not available at Dana-Farber. This information in the clinicaltrials.gov database is not correct.

IPI-504

All new patients are getting the drug on a continuous schedule instead of the 2 weeks on, one week off schedule. Responses are being seen in GIST patient PET scans.

XL-820

The principal investigator at Cancer Therapy and Research Center in San Antonio, TX has changed from Dr. Papadopoulos to Dr. Catalin Mita. The contact is: Epp Goodwin, Clinical Trials Referral Coordinator, CTRC-Grossman Bldg, 7979 Wurzbach Road, San Antonio, TX 78229, Phone: 210-450-5798, E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

CNF2024

The contact at the Cancer Therapy and Research Center in San Antonio, TX is: Epp Goodwin, Clinical Trials Referral Coordinator, CTRC-Grossman Bldg, 7979 Wurzbach Road, San Antonio, TX 78229, Phone: 210-450-5798, E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

AZD-2171

The contact number outside the United States is: 001-866-992-9276.

 

To view the latest clinical trials, visit: http://www.liferaftgroup.org/docs/gist_clinical_trial_datasheets.htm.htm


0 Votes

0 Comments

Add Comment